US20110288283A1 - Process for producing glycosaminoglycans - Google Patents
Process for producing glycosaminoglycans Download PDFInfo
- Publication number
- US20110288283A1 US20110288283A1 US13/002,765 US200913002765A US2011288283A1 US 20110288283 A1 US20110288283 A1 US 20110288283A1 US 200913002765 A US200913002765 A US 200913002765A US 2011288283 A1 US2011288283 A1 US 2011288283A1
- Authority
- US
- United States
- Prior art keywords
- membrane
- homogenate
- glycosaminoglycan
- eluate
- elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 77
- 239000012528 membrane Substances 0.000 claims abstract description 94
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 17
- 239000012504 chromatography matrix Substances 0.000 claims abstract description 16
- 229920000669 heparin Polymers 0.000 claims description 46
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 40
- 229960002897 heparin Drugs 0.000 claims description 37
- 210000000936 intestine Anatomy 0.000 claims description 22
- 241000972773 Aulopiformes Species 0.000 claims description 15
- 239000011159 matrix material Substances 0.000 claims description 15
- 235000019515 salmon Nutrition 0.000 claims description 15
- 241000239366 Euphausiacea Species 0.000 claims description 14
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 229940127219 anticoagulant drug Drugs 0.000 claims description 11
- 238000005194 fractionation Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 96
- 238000010828 elution Methods 0.000 description 48
- 239000011780 sodium chloride Substances 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 239000000284 extract Substances 0.000 description 25
- 239000006167 equilibration buffer Substances 0.000 description 23
- 239000007979 citrate buffer Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 12
- 239000003055 low molecular weight heparin Substances 0.000 description 12
- 229940127215 low-molecular weight heparin Drugs 0.000 description 12
- 150000001450 anions Chemical class 0.000 description 10
- 241000251468 Actinopterygii Species 0.000 description 9
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000019688 fish Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000004365 Protease Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002816 gill Anatomy 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 108090000526 Papain Proteins 0.000 description 7
- 238000005349 anion exchange Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229940055729 papain Drugs 0.000 description 7
- 235000019834 papain Nutrition 0.000 description 7
- 239000013017 sartobind Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012901 Milli-Q water Substances 0.000 description 6
- 239000004019 antithrombin Substances 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 238000005341 cation exchange Methods 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000011362 coarse particle Substances 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000252203 Clupea harengus Species 0.000 description 3
- 241000276438 Gadus morhua Species 0.000 description 3
- 229920001499 Heparinoid Polymers 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- -1 benzyl ester Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 235000019516 cod Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000002554 heparinoid Substances 0.000 description 3
- 235000019514 herring Nutrition 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 241000252073 Anguilliformes Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241001454694 Clupeiformes Species 0.000 description 2
- 241001149724 Cololabis adocetus Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241000212925 Meganyctiphanes norvegica Species 0.000 description 2
- 241000276495 Melanogrammus aeglefinus Species 0.000 description 2
- 241001502129 Mullus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000269908 Platichthys flesus Species 0.000 description 2
- 241000269980 Pleuronectidae Species 0.000 description 2
- 241000612182 Rexea solandri Species 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- 241000269851 Sarda sarda Species 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- 241000269821 Scombridae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241000656145 Thyrsites atun Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 235000019513 anchovy Nutrition 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000020640 mackerel Nutrition 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000003134 recirculating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241001519451 Abramis brama Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000269858 Anarhichas lupus Species 0.000 description 1
- 241000656147 Benthodesmus simonyi Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000276616 Cichlidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000252100 Conger Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241001472118 Euphausia pacifica Species 0.000 description 1
- 241000239370 Euphausia superba Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001125831 Istiophoridae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001417902 Mallotus villosus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000252143 Polyodon spathula Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241001290266 Sciaenops ocellatus Species 0.000 description 1
- 241000630329 Scomberesox saurus saurus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241001486863 Sprattus sprattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000010828 animal waste Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000389 anti-prion effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940125682 antidementia agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002086 displacement chromatography Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108010093564 inter-alpha-inhibitor Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229940045627 porcine heparin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0066—Isolation or extraction of proteoglycans from organs
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Definitions
- the present invention relates to processes for the production of glycosaminoglycan (GAG) compositions, preferably compositions comprising anticoagulant GAGs such as heparins.
- GAG glycosaminoglycan
- the glycosaminoglycans are extracted from non-mammalian marine animals, such as fish or krill.
- Glycosaminoglycans consist of two sub-groups namely, galactosaminoglycans and glucosaminoglycans.
- Heparin is the name given to a class of sulphated glucosaminoglycans having anticoagulant properties.
- other anticoagulant sulphated glucosaminoglycans (often referred to as heparinoids) are known, e.g. heparan sulphate. These too have been used to achieve anti-coagulant or anti-opsonization effects.
- heparin is the most commercially significant of the group.
- the anticoagulant glycosaminoglycans are polysaccharides with repeating sulphated disaccharide units.
- the polysaccharide structure may additionally contain other oligosaccharide substructures, e.g. the pentasaccharide unit known to bind to antithrombin.
- heparin contains additional saccharide units, e.g. disulphated disaccharides, and some heparin contains the pentasaccharide which is a high affinity binding site for antithrombin. Heparin containing this pentasaccharide binding site for antithrombin is known as high affinity heparin.
- glycosaminoglycans differ in the inter-saccharide bonds and the saccharide ring substitution. Moreover, for a particular animal species, the chain length varies and thus the glycosaminoglycans have molecular weight distributions rather than specific molecular weights, i.e. they are polydisperse.
- Heparin has a polymeric structure and thus heparin compositions generally contain heparins having a range of molecular weights, typically from 3 kDa to 40 kDA. Heparin with this wide range of molecular weights is usually referred to as unfractionated heparin (UFH). As currently used commercially, UFH typically has molecular weights in the range 5.0 to 40 kDa.
- LMWH low molecular weight heparin
- LMWH low molecular weight heparin
- LMWH has a potency of at least 70 units/mg of anti-factor Xa activity and a ratio of anti-factor Xa activity to anti-factor IIa activity of at least 1.5.
- LMWH can be produced from native unfractionated heparin by a variety of processes, e.g. by fractionation or depolymerisation by chemical or enzymatic cleavage, e.g. by nitrous acid depolymerisation, oxidative depolymerisation with hydrogen peroxide, deaminative cleavage with isoamyl nitrite, alkaline beta-eliminative cleavage of the benzyl ester of heparin, oxidative depolymerisation with Cu 2+ and hydrogen peroxide or by heparinase digestion.
- processes e.g. by fractionation or depolymerisation by chemical or enzymatic cleavage, e.g. by nitrous acid depolymerisation, oxidative depolymerisation with hydrogen peroxide, deaminative cleavage with isoamyl nitrite, alkaline beta-eliminative cleavage of the benzyl ester of he
- VLMWH very low molecular weight heparin
- Marine GAGs e.g. heparin extracted from marine animals
- the extraction of marine heparin is described in WO 02/076475, the contents of which are hereby incorporated by reference.
- Previous methods for extracting GAGs from marine material include ion exchange chromatography, electrophoretic separation, sequential precipitation in various organic solvents and various other methods, including those described in the prior art for extraction from animal sources. Many of these techniques are time consuming and inefficient, thus there exists a need for alternative processes for the production of GAGs of marine origin. For example, AT-Sepharose chromatography purifies only the high affinity parts of heparin, whereas, the Applicant has found, conventional bead-based ion exchange systems may also bind unwanted compounds such as lipids. Moreover, in these known techniques, washing must be performed for an extended period of time and high volumes of buffer solutions are required in order to elute the GAGs from the columns (this makes further processing laborious). This leads to problems such as oxidation, precipitation and lack of activity.
- the Applicant has further identified that existing methods for extraction of GAGs from marine animal material may suffer from problems such as unfeasibly long processing times (i.e. up to several days, which can result in release of the odour of decaying fish waste) and low total activity of the resulting product.
- the invention provides a process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing non-mammalian marine animal material to chromatography using a chromatographic matrix, preferably in the form of a membrane adsorber.
- the invention provides a process for extracting glycosaminoglycans from glycosaminoglycan-containing non-mammalian marine animal material said method comprising homogenising said animal material and subjecting the homogenate to chromatography using a chromatographic matrix, preferably in the form of a membrane adsorber.
- the homogenate is repeatedly applied to the chromatographic matrix.
- the chromatographic matrix is a membrane adsorber.
- Membrane adsorbers offer an alternative to traditional bead-based chromatography columns. They are typically based on a chemically stable cellulosic membrane to which a variety of chromatography ligands can be covalently bound. The membrane typically achieves separation by reversible binding of the target molecules to the ligand via their functional groups in a manner analogous to ion exchange chromatography.
- Typical ligands types are strong/weak anion or cation exchange ligands, metal chelates, epoxy and aldehyde ligands.
- Cationic exchange membranes comprise ligands which contain anionic function groups such as —SO 3 ⁇ , —OPO 3 ⁇ and —COO ⁇ , e.g. carboxymethyl (CM), sulphopropoyl (SP) and methyl sulphonate (S).
- Anionic exchange membranes typically contain ligands with cationic functional groups such as —NHR 2 + and —NR 3 + , e.g. diethylaminoethyl (DEAE), quaternary aminoethyl (QAE) and quaternary ammonium (Q). Quaternary ammonium (Q) is particularly preferred for use in the present invention.
- Membrane adsorbers are macroporous and their major kinetic effect is believed to be convective flow and rapid film diffusion.
- the adsorbers allow large flow rate ranges without the diffusion limitations found with conventional chromatographic bead/resins etc.
- Membrane adsorbers can be used in a variety of chromatographic applications. Current uses are for the removal of DNA, viruses and endotoxins from pharmaceutical proteins and the purification of viruses, proteins and peptides from solutions. The advantages achieved by the application of this technique to polysaccharides have not previously been appreciated.
- Single use, disposable membrane adsorbers are available, as are membranes which can be reused after suitable treatment.
- Suitable systems for use in the process of the invention are the Sartobind Membrane Adsorbers available from Sartorius (e.g. Sartobind Anion Direct).
- the use of a membrane adsorber according to the invention removes the requirement for costly and time consuming column packing and cleaning validation associated with bead-based chromatography systems. It also allows the required number and volume of buffers to be minimised.
- Use of membrane adsorbers in chromatography allows the process time and buffer usage to be reduced.
- the adsorbers allow large flow rate ranges and have high binding capacities. Their open structures allows a wide-range of volumes, flow-rates etc. to be used and provide a large surface area for sample/ligand interaction.
- the process of the invention may be a batch process or a column process.
- the variety of bed-volumes allows the technique to be highly flexible and easy to scale-up.
- the high volume throughput obtainable with membrane adsorbers makes the process of the invention highly productive compared with conventional methods.
- the homogenate is extracted from the waste from animal material, e.g. a non-mammalian marine animal after removal of muscle tissue, e.g. for use as a human foodstuff.
- animal material e.g. a non-mammalian marine animal after removal of muscle tissue, e.g. for use as a human foodstuff.
- non-mammalian marine animal material material derived from fresh-water as well as salt-water fish, shellfish and crustaceans, such as krill.
- Non-mammalian marine animals used as food sources for mammals or as raw materials for fish meal, fish food, and fish oil are preferred. Particularly preferably, farmed non-mammalian marine animals are used.
- non-mammalian marine animals include: prawns, shrimp, krill, carp, barbell and other cyprinids; cod, hake, haddock; flounder; halibut; sole; herring; sardine; anchovy; jack; mullet; saury; mackerel; snoek; cutlass fish; red fish; bass; eels (e.g. river eels, conger, etc.); paddle fish; tilapia and other cichlids; tuna; bonito; bill fishes; diadromous fish; etc.
- suitable fish include: flounder, halibut, sole, cod, hake, haddock, bass, jack, mullet, saury, herring, sardine, anchovy, tuna, bonito, bill fish, mackerel, snoek, shark, ray, capelin, sprat, brisling, bream, ling, wolf fish, salmon, trout, coho and chinock.
- the non-mammalian marine animal used is trout, salmon, cod or herring, more especially salmon or hill.
- Krill are particularly preferred, for example Antarctic hill ( Euphausia superba ), Pacific krill ( Euphausia pacifica ) and Northern krill ( Meganyctiphanes norvegica ).
- glycosaminoglycan-containing non-mammalian marine animal waste used as the source for heparin extraction will typically be selected from heads, skin, gills, and internal organs.
- the use of gills alone, of heads and of internal organs is especially preferred.
- Methods of processing fish waste are known from the literature, e.g. WO2004/049818.
- the homogenate of the animal material can be prepared by standard methods, e.g. physical or chemical pretreatment, e.g. maceration, acid or base treatment, etc., in particular grinding or blending.
- the homogenate may be further treated in order to remove particulate material, for example via centrifugation and/or filtration.
- this is not always necessary, for example we have surprisingly found that crude homogenate can be applied directly to the membrane (conventional chromatography generally requires more extensive pre-treatment steps).
- the homogenates are preferably centrifuged or otherwise subjected to fines-removal, particularly if the source is fish gill material.
- the homogenate is treated with an enzyme, particularly a protease such as papain in order to digest the proteins present in the homogenate, prior to application to the membrane system.
- an enzyme particularly a protease such as papain
- the homogenate may be heated to 50 to 200° C., preferably 70 to 120° C., especially preferably, 80 to 100° C., e.g. around 80° C. in order to inactivate the proteins.
- the pH of the sample should be adjusted such that it is at least 1.0 above or below the isoelectric point of the desired GAG (for anion- or cation-exchange respectively).
- Anion exchange is preferred for the GAG extraction of the present invention, in which case a pH of around 5 is preferred.
- the pH of the membrane may be stabilized prior to sample application, for example by using an equilibrium buffer.
- Equilibrium buffers (and other conditions and methods) used in standard chromatographic separation techniques may be used in the process of the invention.
- suitable buffers which may include a salt, such as NaCl
- suitable buffers are NH 4 Ac/HAc, Bis-Tris/HCl and citrate buffer, e.g. 5 mM NH 4 Ac/HAc, 10 mM NaCl/25 mM NH 4 Ac/HAc, 10 mM NaCl/25 mM Bis-Tris/HCl and 10 mM NaCl/25 mM citrate buffer.
- Suitable equilibration buffers for use in the invention when a cation exchange membrane is utilised are; citrate, formate, acetate, malonate, MES, phosphate etc.
- the pH of the equilibrium buffer will be 4.5 to 10, preferably 5 to 6.5, e.g. around 5.5.
- much lower pHs are required, e.g. 1 to 4, preferably around 2.
- the method of the present invention enables the sample (homogenate) to be recirculated, and thus the exposure of the sample to the matrix can be controlled.
- Said recirculation can be achieved in any convenient manner, for example by positioning the inlet and outlet tubings in the same vessel.
- the homogenate can therefore be repeatedly applied to the chromatographic matrix.
- the homogenate is repeatedly applied to the matrix (e.g. the membrane adsorber) by recirculating the homogenate. That is, the flow-through (i.e. any material not bound to the matrix) is reapplied to the matrix, preferably immediately following it leaving the membrane adsorber (i.e. before elution of eluate).
- the homogenate is recirculated, i.e.
- Typical application times are 5 minutes to 3 hours, preferably 15 minutes to 2 hours, more preferably 30 minutes to 1.5 hours, especially preferably 45 minutes to 1 hour.
- a typical residence time for a 2.5 ml membrane in recirculation mode for 30 minutes is around 2.8 s.
- the present invention provides a process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing non-mammalian marine animal material to chromatography using a chromatographic matrix, wherein said homogenate is repeatedly applied to said matrix.
- the matrix is preferably in the form of a membrane adsorber as herein described.
- the bound GAG compounds can be eluted. Elution may be effected using step-wise increases in ionic strength and/or changes in pH, or a suitable gradient. Preferably, elution is carried out using a suitable elution buffer. Clearly these will depend on the nature of the stationary phase. For anion exchange, the pH of the elution buffer will be 4.5 to 10, preferably 5 to 6.5, e.g. around 5.5.
- Suitable elution buffers for use in anion exchange methods according to the invention are those in which the concentration of the mobile phase counter ion is increased. This is conveniently effected by adding NaCl to the equilibrium buffer. 1-15M, preferably 2-20M, e.g. 3-4M NaCl is typically used for anion exchange methods e.g. buffers such as 1-4 M NaCl in 5 mM NH 4 Ac/HAc, 3 M NaCl in 25 mM NH 4 Ac/HAc, 10 mM NaCl in 25 mM citrate buffer, 3.5 M NaCl/5 mM citrate buffer.
- buffers such as 1-4 M NaCl in 5 mM NH 4 Ac/HAc, 3 M NaCl in 25 mM NH 4 Ac/HAc, 10 mM NaCl in 25 mM citrate buffer, 3.5 M NaCl/5 mM citrate buffer.
- Suitable elution buffers for use in the invention when a cation exchange membrane is utilised are; citrate, formate, acetate, malonate, MES, phosphate. In both cases the pHs are similar to those outlined for the equilibrium buffers above.
- the GAG-containing composition of the process may be concentrated, desalted and/or dried before further handing. Freeze drying is preferred.
- the eluate is desalted, e.g. using a Millipore/Amicon stirred cell with a Nanomax-50 filter, and then freeze-dried. This is particularly useful if the unfractionated product (UFH) is to be fractionated as it removes the salt and minimizes the volume of the redissolved sample to be applied to a size exclusion chromatography (SEC) column, e.g. a G-75 Sephadex column.
- UH unfractionated product
- SEC size exclusion chromatography
- the membrane can be reused after elution, by washing in a suitable buffer solution such that the membrane is regenerated.
- the flow-through i.e. the material which has been applied to the membrane, whether by a single application or using recirculation, but did not bind
- the flow-through can be reapplied to the membrane after the elution step. In this way, the same homogenate can be used until all substantially of the desired GAG has been isolated.
- more than one membrane adsorber can be used, these can be arranged in series or parallel.
- Membrane capacities can be chosen according to the size of the sample, and thus the method is easy to scale up. Typical bed volumes are in the range of from 5 to 2500 ml, whereas membrane areas are typically from 200 cm 3 to 10 m 3 .
- the invention allows use of higher flow rates than conventional ion chromatography. These will depend on the capacity of the membrane. Typical flow rates for a 2.5 ml membrane are, 5 to 60 ml/min, especially 10 to 50 ml, especially preferably 20 to 40 ml/min, for example around 30 ml/min.
- Recirculation time and flow rate can be adjusted according to requirements.
- the total amount of sample exposed to the matrix is the product of recirculation time and flow rate.
- the degree of exposure of the sample to the membrane is defined as (recirculation time ⁇ flow rate)/matrix volume. For example, recirculating at 25 ml/min for 1 hour, results in a volume of 1500 ml being exposed to the matrix (60 min ⁇ 25 ml/min). For a 2.5 ml membrane, this equates to a degree of exposure value of 600 (i.e. 600 ml per ml of membrane).
- the degree of exposure as defined herein is from 50 to 3000, preferably 200 to 1000, especially 400 to 800, more especially 500 to 700, particularly around 600.
- antioxidants may be used in order to avoid any unwanted decomposition.
- Typical membrane binding capacities are >0.8 mg BSA on strong anion, >0.8 mg lysozyme on strong cation.
- Typical static binding capacities are >72 mg/2.5 ml, >720 mg/25 ml, >7200 mg/250 ml;
- the ion capacity (cm 3 ) is usually around 4-6 ⁇ equiv.
- the feed stream is routed tangentially over the membrane layers which are separated by a spacer.
- glycosaminoglycan (GAG) extracted by the process of the invention are preferably glucosaminoglycans, especially those with anticoagulant properties, particularly heparin, a heparinoid, or a low molecular weight heparin or heparinoid, or a mixture of two or more thereof.
- GAG glycosaminoglycan
- it is a sulphated GAG, in particular a heparin or LMWH, especially preferably it is a high affinity GAG.
- anticoagulant it is meant that a GAG has the ability to bind to antithrombin, an inter-alpha-trypsin inhibitor, factor Xa, and other proteins to which mammalian heparin binds, e.g. immobilized on a substrate such as a gel matrix, and/or the ability to delay or prevent clotting in human plasma or to prolong bleeding in a mammal (e.g. a mouse).
- Glycosaminoglycans particularly anticoagulant glycosaminoglycan or glucosaminoglycans, especially preferably heparins extracted from krill, are in themselves novel and inventive and thus form a further aspect of the present invention.
- these glycosaminoglycans are extracted via the processes described herein, however any suitable extraction method may be used, for example those set out in WO 02/076475 and WO 2006/120425.
- Both the krill GAG products mentioned above and the products of the process of the invention constitute a further aspect of the invention.
- These products may be further processed, for example the resulting UFH compositions may be treated (e.g. fractionated or depolymerized) to give compositions enriched or depleted in LMWH and/or VLMWH etc.
- the products of the invention may be used according to the invention in its naturally occurring form following extraction, for example as UFH. However alternatively it may be converted into salt form, preferably with a physiologically tolerable counterion (e.g. sodium, calcium, magnesium, potassium, ammonium or meglumine), or derivatised, e.g. to facilitate its binding to a surface of an item of medical apparatus, or molecular weight fractionated or depolymerised (e.g. to produce a GAG fraction meeting the molecular weight definition for LMWH). As with the products of the processes herein described, such derivatives are preferably physiologically tolerable.
- a physiologically tolerable counterion e.g. sodium, calcium, magnesium, potassium, ammonium or meglumine
- derivatised e.g. to facilitate its binding to a surface of an item of medical apparatus
- molecular weight fractionated or depolymerised e.g. to produce a GAG fraction meeting the molecular weight definition for LMWH.
- the product of the chromatographic process is then fractionated and/or depolymerised.
- fractionation is achieved by filtration (e.g. membrane filtration) or chromatographically, especially preferably using size exclusion chromatography, ion exchange chromatography, or sample displacement chromatography. Suitable methods are set out in WO 2006/120425.
- the marine GAG composition is concentrated and desalted before further processing such as fractionation.
- the marine GAGs of the invention are subjected to membrane filtration to remove low molecular weight components, e.g. with a molecular weight before that of the antithrombin binding pentamer (MW 1728 Da), typically using a membrane with a 1 kDa cut-off (e.g. Omega-1k Ultrasette from Filtron/Pall, Millipore Pellicon 1 kDa cut-off).
- a membrane with a 1 kDa cut-off e.g. Omega-1k Ultrasette from Filtron/Pall, Millipore Pellicon 1 kDa cut-off
- the marine GAGs are subjected to membrane filtration to remove high molecular weight components, for example with a molecular weight cut-off of 3000 Da (e.g. using Omega Centramate Suspended Screen OS005C11P1 from Filtron/Pall).
- LMWH- and/or VLMWH-enriched fractions in addition to the UFH product.
- Such fractions can be used separately, in combination (e.g. in combination therapy) or blended to provide GAG compositions to meet a variety of requirements.
- the product may be fractionated to produce a fraction enriched in LWMH or VLMWH.
- the remaining fraction, depleted in either LMWH or VLMWH, may be retained and used alone or added to further unfractionated product. In this way waste of the products is minimised.
- compositions produced according to the process of the invention and described herein may be dried or may be formulated for use, e.g. with a diluent, carrier or an active drug substance, and it may be applied, preferably after formulation with a liquid carrier, as a coating to the surface of a medical instrument, e.g. a catheter or implant.
- a medical instrument e.g. a catheter or implant.
- Such compositions and coated instruments form further aspects of the present invention, as does the process for their preparation, e.g. by admixing or coating.
- the invention provides a non-mammalian marine animal glycosaminoglycan composition produced by the processes herein described, optionally further containing a physiologically acceptable carrier or excipient and/or a drug substance and optionally coated onto a substrate.
- a physiologically acceptable carrier or excipient for use in medicine or therapy form a further aspect of the present invention.
- the invention provides a hill glycosaminoglycan composition, optionally further containing a physiologically acceptable carrier or excipient and/or a drug substance and optionally coated onto a substrate.
- a hill glycosaminoglycan composition optionally further containing a physiologically acceptable carrier or excipient and/or a drug substance and optionally coated onto a substrate.
- the invention provides the use of a composition according to the invention or produced according to the process of the invention, or a salt or derivative thereof, in mammalian, especially human, medical treatment, e.g. in compositions or equipment used in surgery, therapy, prophylaxis, or diagnosis on human or non-human animal subjects or for blood contact.
- the compositions are fractionated (e.g. according to activity or molecular weight) to provide compositions enriched in certain fractions, e.g. VLMWH.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising hill GAGs or non-mammalian marine animal GAGs produced by the process herein described or a salt or derivative thereof together with a physiologically tolerable carrier or excipient, and optionally also a therapeutic or prophylactic drug substance.
- the GAG compositions according to the invention may further contain non-GAG components conventional in mammalian GAG compositions, e.g. water (preferably water for injections), ethanol, buffers, osmolality adjusting agents, preservatives, etc.
- non-GAG components conventional in mammalian GAG compositions, e.g. water (preferably water for injections), ethanol, buffers, osmolality adjusting agents, preservatives, etc.
- the GAGs of the invention may be used as antithrombotics, anti-atherosclerotics, complement inhibitors, anti-inflammatories, anti-cancer agents, anti-viral agents, anti-dementia agents (e.g. anti-Alzheimer agents), anti-prion agents, anti-parasitics, opsonization inhibitors, biomaterials, angiogenesis regulators, and in the treatment of vascular deficit, wounds and immune response disorders (e.g. AIDS), etc. They may be administered enterally or parenterally, e.g. orally or subcutaneously or bound to an object or drug material placed into tissue or the circulatory system.
- the GAGs of the invention may be used for diagnostic purposes, e.g. diagnostics assays, and non-medical uses for which heparin is suited or currently used.
- diagnostic assay kit comprising an anticoagulant, characterised in that said anticoagulant is a glycosaminoglycan according to the invention.
- the process of the invention has been carried out on mammalian material and has been found to be equally applicable to mammalian material as it is to material of non-mammalian marine animal origin.
- the glycosaminoglycan-containing mammalian material used as the source for heparin production/extraction according to this aspect of the present invention is preferably waste from meat-processing, i.e. waste following the extraction of material for food. Intestines, preferably bovine or porcine intestines, are thus preferred sources.
- mammalian material preferably non-human mammalian intestinal material
- non-mammalian marine animal material thus form further aspects of the present invention.
- the present invention provides a process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing mammalian intestines to chromatography using a chromatographic matrix in the form of a membrane adsorber.
- a process for the production of a glycosaminoglycan composition said process comprising subjecting a homogenate of glycosaminoglycan-containing mammalian intestines to chromatography using a chromatographic matrix (preferably a membrane adsorber) wherein said homogenate is repeatedly applied to said matrix is also provided.
- the mammal from which the mammalian material is derived is a non-human mammal.
- suitable mammals include cattle, goats, sheep, deer, pigs, swine, boar etc. Bovine and porcine materials are especially preferred.
- the pump used was a Pump Masterflex I/P, except for elution where a peristaltic Pharmacia P-1 pump was used.
- the membrane used was a 2.5 ml Sartobind® Anion Direct, Strong basic anion exchanger membrane.
- a salmon intestine extract was prepared by homogenizing 280 g salmon intestines in Milli-Q water.
- the theoretical amount of GAG (glycosaminoglycan) as measured by the carbazole method was calculated as 98 mg (N.B. the carbazole test results in a red/violet colour for glycosaminoglycans which contain uronic acid).
- Proteins were degraded by papain at 55° C., then inactivated by heating to 80° C. Coarse particles were removed by filtering through a nylon filter. The extract was then adjusted to pH 5.5 by adding 0.5 M ammonium acetate/acetic acid (pH 5.5) to 25 mM (final concentration of acetate) and NaCl (final concentration of 10 mM). The pH was measured as 6.08.
- Elution 1 The resulting extract was then recirculated (by immersing the inlet and outlet of the tubing in the same beaker) on a the membrane at around 25 ml/min for 64 minutes and then washed with 150-200 ml of the equilibration buffer (25 mM acetate/acetic acid/10 mM NaCl, pH 5.5). Elution was then carried out using 20 ml 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (Eluate no. 1).
- Elution 2 The membrane was then washed with equilibration buffer and the extract (i.e. the flow-through from Elution 1) was applied again, this time for 45 min. It was washed with equilibration buffer (150-200 ml) and allowed to stand overnight. Elution was then carried out using 20 ml 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (Eluate no. 2).
- Elution 3 The membrane allowed to stand in 1 M NaOH for around 1 hour and was then washed with equilibration buffer. The extract (i.e. the flow-through from Elution 2) was applied again for 55 min, washed with equilibration buffer, then eluted in 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (Eluate No. 3).
- Elution 4 The membrane allowed to stand with 1 M NaOH for around 1 hour and was then washed with equilibration buffer. The extract (i.e. the flow-through from Elution 3) was applied again for 51 min, washed with equilibration buffer, then eluted in 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (Eluate No. 4).
- Elution 5 The equilibration buffer was then changed to 25 mM NH 4 Ac/HAc, pH 5.0/10 mM NaCl and pH in the extract (i.e. the flow-through from Elution 4) adjusted to 4.96 (using 6 M HCl). This was circulated on the membrane for 60 min, and the membrane was then washed with 200 ml of the equilibration buffer. Eluate no. 5 was obtained using 20 ml 3 M NaCl in 25 mM NH 4 Ac/HAc, pH 5.0.
- Elution 6 The pH of the extract (i.e. the flow-through from Elution 5) was then adjusted to 5.5 (using 3M NaOH), and the membrane was washed with in 25 mM NH 4 Ac/HAc, pH 5.5/10 mM NaCl. The extract was recirculated on the membrane for 60 minutes. Eluate no. 6 was obtained using 3 M NaCl (20 ml) in 5 mM NH 4 Ac/HAc, pH 5.5.
- Elution 7 The membrane was kept in 20% EtOH in equilibration buffer overnight and then treated with 1 M NaOH for around 45 minutes, then washed. The extract (i.e. the flow-through from Elution 6) was recirculated for 60 minutes on the membrane. Eluate no. 7 was obtained using 3 M NaCl (20 ml) in 5 mM NH 4 Ac/HAc, pH 5.5.
- the pooled eluates (i.e. Eluates 1 to 7 are combined) were concentrated and desalted for biological tests.
- the salmon homogenate that had been passed 7 times on the membrane was kept at +4° C. and pH was adjusted to 6.0 with Bis-Tris (i.e. Bis(2-hydroxyethyl)amino-Tris(Hydroxy-methyl)methane).
- the membrane was washed 3 times with 1 M NaOH (with buffer washings of 25 mM Bis-Tris/HCl/10 mM NaCl, pH 6.0 in-between) and then equilibrated with 25 mM Bis-Tris/HCl/10 mM NaCl, pH 6.0 (the equilibration buffer).
- the homogenate was recirculated on the membrane at room temperature for 60 minutes at a flow rate of 25 ml/min.
- the in/out tubings were in the same beaker, as in Example 1, with the inlet at the bottom and the outlet on the top.
- elution was carried out using 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (as previously). The volume of the eluate was 24.4 ml.
- the total amount of uronic acid-containing GAG as measured by the carbazole test was 0.933 mg.
- the combined eluates (1 to 7) from Example 1 were concentrated and desalted on a Millipore Pellicon 1000 MWCO membrane using tangential flow.
- the sample i.e. everything from the eluates of Example 1 which has a molecular weight above 1000 Da
- the white, powder-like residue obtained had a weight of 630 mg.
- the homogenate that had been passed 8 times on the membrane was recirculated again on the membrane for 1 hour (following storage for four days in a refrigerator) using a flow rate of 25 ml/min.
- the homogenate was then washed with equilibration buffer (25 mM Bis-Tris, pH 6.0/10 mM NaCl). Elution was performed using 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (as previously).
- a salmon gill extract was made by homogenizing 444.4 g salmon gills (the gills were cut out, leaving the cartilage, gristle) in Milli-Q water. Proteins were degraded by papain at 55° C., then inactivated by heating to 80° C. Coarse particles were removed by filtering through a nylon filter. The pH in the homogenate was measured to 6.81, this was adjusted using 6 M HCl to 6.0.
- the homogenate was centrifuged (12,000 rpm for 30 minutes). The supernatant was saved and, prior to each elution step was recirculated on the membrane for 60 minutes using a flow rate of 25 ml/min.
- Elution 1 Washing and elution (Eluate no. 1) was carried out with 3 M NaCl/5 mM Bis-Tris, pH 6.0.
- Elution 2 The membrane was treated with 1 M NaOH for 45 minutes before the next recirculation (of the flow-through from Elution 1), washing and elution were carried out as described above (Eluate no. 2).
- the amount of uronic acid-containing glucosaminoglycan was determined using the carbazole test in triplicate for each eluate:
- the pooled extracts (eluates 1 to 3) were desalted, concentrated and freeze-dried (as described in Example 5). The weight of the freeze-dried sample was around 61 mg. The freeze-dried eluate was a white, fluffy powder. An activity test gave a total of 2.56 U in 61 mg.
- the pooled eluates (4 to 6) were desalted, concentrated and freeze-dried.
- the membrane was then equilibrated using 25 mM Bis-Tris/10 mM NaCl, pH 6.0 and the flow-through from Elution 6 was recirculated on the membrane for 1 hour using a flow rate of 25 ml/min and eluted using 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5 (Eluate 7).
- the homogenate i.e. the flow-through from Eluate 7) was then adjusted to pH 7.0 using 4 M NH 3 .
- the membrane was equilibrated using NH 4 Ac/HAc, pH 7.0. and the homogenate was recirculated on the membrane for 1 hour using a flow rate of 25 ml/min, then eluted as above (Eluate 8).
- the results of the carbazole test of Eluates 7 and 8 are shown below:
- the pool of intestine extracts i.e. the combined eluates 1 to 7 from Example 1 was concentrated and desalted on Millipore Pellicon 0.5 m 2 1000 MWCO-membrane (tangential flow), then freeze-dried.
- the resulting freeze dried sample has a weight of around 630 mg, an aliquot of 21.5 mg was submitted to activity testing at the Central Laboratory, Aker University Hospital, Norway.
- Example 6 The eluate from Example 6 (i.e. that from intestine homogenate of Example 3 and kept in fridge when not in use) was desalted and concentrated in Amicon stirred cell with 1000 MWCO, total weight: 0.269 g, aliquot to test: 0.020 g.
- An extract from salmon intestines (498 g, stored at ⁇ 20° C.) was made by homogenizing the salmon intestines in 498 ml Milli-Q water, using a Braun handheld homogenizer for a few minutes. Protein digestion was carried out at 55° C. for 3 hours, using 0.5 g papain, followed by inactivation at 80° C. for 1 hour.
- the homogenate was filtered through a nylon filter, removing the course particles.
- the pH of the filtrate was adjusted to 6.2 using 0.5 M citrate buffer, pH 6.2.
- the final volume was 1000 ml which was divided into 5 aliquots of 200 ml and kept at +4° C. when not in use.
- the membrane was treated with 1 M NaOH for 1 hour between every use.
- the equilibration buffer was 25 mM citrate buffer, pH 6.2/10 mM NaCl in all experiments described in this Example. In each case elution was performed using 25 mM citrate buffer, pH 6.2/10 mM NaCl.
- the homogenate was recirculated for the given period of time, then washed with ca. 100-120 ml of the equilibration buffer and eluted.
- glycosaminoglycan was determined by measuring the volume of the eluates and performing the carbazole test using 3-4 aliquots of 3 ⁇ l (12 ⁇ g) unfractionated porcine heparin for standard and 3-7 aliquots (200 ⁇ l) of the eluates.
- the recirculation speed was 9.7 ml/min, using the Pharmacia P-1 pump and the last 200 ml aliquot of the homogenate. Recirculation was performed for 1 hour and elution speed was as above. The total amount of GAG detected was 1.843 mg.
- Example 7 The 5 aliquots used in Example 7 were pooled, mixed and divided into 5 equal aliquots. The contents of aliquot 1 were centrifuged at 12 000 rpm (23 975 ⁇ g) for 30 minutes. The supernatant was pipetted off, taking care to avoid the lipid layer and the precipitate.
- This supernatant was then recirculated (22 ml/min) on the Sartobind Anion Direct membrane for 1 hour.
- the membrane was equilibrated against 25 mM citrate buffer pH 6.2/10 mM NaCl. After recirculation, the membrane was washed with the equilibration buffer (110-120 ml) and eluted using 20 ml 3.5 M NaCl in 5 mM citrate buffer pH 6.2. The membrane was incubated with 1 M NaOH for 1 hour, then washed against the pH 6.2 equilibration buffer.
- the volume and amount of GAG was determined:
- a further advantage of this method is that crude or fines-filtrated homogenate can be applied, while conventional anion chromatography requires a more extensive centrifugation or filtration.
- the effect of pH was also investigated.
- the pH was checked in a 3rd homogenate-aliquot and found to be 6.73, in spite of the pH-adjustment in Example 9.
- the pH in this aliquot was adjusted to 5.5 using solid citric acid.
- the membrane was equilibrated with 25 mM citrate buffer pH 5.5/10 mM NaCl.
- the homogenate was recirculated (22 ml/min) for 1 hour, washed (110-120 ml) and eluted using 3.5 M NaCl/5 mM citrate buffer, pH 5.5.
- Example 7 The remaining two aliquots from Example 7 were used. The speed of recirculation was calibrated to 44 ml/min.
- the equilibration buffer was 25 mM citrate buffer, pH 6.2/10 mM NaCl, the elution buffer was 3.5 M NaCl in 5 mM citrate buffer, pH 6.2.
- the elution speed was 1.4 ml/min (as in Example 7).
- the pH of the two homogenates was adjusted to 6.2 using solid citric acid.
- the volume and GAG-content (carbazole-test, 4 ⁇ 200 ⁇ l samples of eluate and 4 ⁇ 3 ⁇ l of standard) was determined in the two eluates.
- the remains of the salmon intestine homogenate from Example 7 were pooled and divided into 5 aliquots of 189 ml and kept at +4° C. until use. Aliquot no. 1 was taken out, the pH adjusted to pH 5.5 using solid citric acid. This was recirculated on the equilibrated (25 mM citrate buffer, pH 5.5/10 mM NaCl) Sartobind Direct Anion membrane for 1 hour at 25° C. and with a pump (MasterFlex I/P) speed of 22 ml/min. The membrane was washed with 110-120 ml of the equilibration buffer. Elution was performed using 3.5 M NaCl/5 mM citrate buffer, pH 5.5 (20 ml).
- Elution was performed using first 20 ml 50 mM citrate buffer, pH 2.8, followed by 20 ml 500 mM citrate buffer, pH 2.8, in separate eluates.
- the GAG content was determined using the carbazole test.
- the precise volume of the eluates (ca. 20 ml each) were determined as set out in the following table.
- Example 10 The last aliquot from Example 10 was recirculated on the membrane by keeping the inlet and the outlet tubing in separate beakers. The complete contents of the outlet beaker was transferred to the inlet beaker once this was emptied. This was performed for 1 hour (effective time) at 27° C. at the speed of 22 ml/min.
- the membrane was calibrated with 25 mM citrate buffer, pH 5.5/10 mM NaCl. The pH of the aliquot was adjusted to 5.5 before its use.
- a krill extract is made by homogenizing 400 g frozen krill in Milli-Q water. Proteins are degraded by papain at 55° C., then inactivated by heating to 80° C. Coarse particles are removed by filtering through a nylon filter. The pH in the homogenate is adjusted using 6 M HCl to 6.0. The homogenate is centrifuged (12,000 rpm for 30 minutes).
- the resulting extract is then recirculated (by immersing the inlet and outlet of the tubing in the same beaker) on a Sartobind® Anion Direct, Strong basic anion exchanger membrane at 25 ml/min for 60 minutes and then washed with 200 ml of equilibration buffer (25 mM acetate/acetic acid/10 mM NaCl, pH 5.5). Elution is then carried out using 20 ml 3 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5. Further elutions are carried out as stated above. The amount of uronic acid-containing glycosaminoglycan is determined using the carbazole test.
- Pig intestines were collected fresh from slaughter and kept on ice. The intestines were emptied of their contents and washed in tap water. 444 g of washed intestines were added to 444 ml of Milli-Q water and homogenized. Proteins were degraded by using papain at 55° C. for 3 hours, then inactivated at 80° C. for 1 hour. Coarse particles were removed by filtering through a nylon filter. The extract was then added to 0.5 M ammonium acetate/acetic acid (pH 5.5) to 25 mM (final concentration of acetate) and NaCl (final concentration of 10 mM). The pH was adjusted to 5.50 by adding 50% (v/v) acetic acid.
- the resulting extract was then recirculated (by immersing the inlet and outlet of the tubing in the same beaker) on a membrane at around 25 ml/min for 45 minutes and then washed with 150-200 ml of the equilibration buffer (25 mM acetate/acetic acid/10 mM NaCl, pH 5.5). Elution was then carried out using 20 ml 4 M NaCl in 5 mM NH 4 Ac/HAc, pH 5.5. The total amount of glycosaminoglycan in the eluate was determined as 0.515 mg using the carbazole test. The eluate was desalted and concentrated in an Athicon stirred cell w/1000 MWCO-filter. The freeze-dried eluate was tested for heparin activity at the Clinical Chemistry Core Unit, Aker University Hospital using the Stachrom Heparin Diagnostica assay. This gave a total of 3.7 antifactor Xa units.
Abstract
The invention provides a process for the production of a composition comprising a glycosaminoglycan, said process comprising subjecting a homogenate of glycosaminoglycan-containing animal material to chromatography using a chromatographic matrix in the form of a membrane adsorber.
Description
- The present invention relates to processes for the production of glycosaminoglycan (GAG) compositions, preferably compositions comprising anticoagulant GAGs such as heparins. Especially preferably, the glycosaminoglycans are extracted from non-mammalian marine animals, such as fish or krill.
- Glycosaminoglycans consist of two sub-groups namely, galactosaminoglycans and glucosaminoglycans. Heparin is the name given to a class of sulphated glucosaminoglycans having anticoagulant properties. Besides heparin, other anticoagulant sulphated glucosaminoglycans (often referred to as heparinoids) are known, e.g. heparan sulphate. These too have been used to achieve anti-coagulant or anti-opsonization effects. However, heparin is the most commercially significant of the group.
- The anticoagulant glycosaminoglycans are polysaccharides with repeating sulphated disaccharide units. The polysaccharide structure may additionally contain other oligosaccharide substructures, e.g. the pentasaccharide unit known to bind to antithrombin. Thus, besides its trisuiphated disaccharide repeat unit, heparin contains additional saccharide units, e.g. disulphated disaccharides, and some heparin contains the pentasaccharide which is a high affinity binding site for antithrombin. Heparin containing this pentasaccharide binding site for antithrombin is known as high affinity heparin.
- The different glycosaminoglycans differ in the inter-saccharide bonds and the saccharide ring substitution. Moreover, for a particular animal species, the chain length varies and thus the glycosaminoglycans have molecular weight distributions rather than specific molecular weights, i.e. they are polydisperse.
- Heparin has a polymeric structure and thus heparin compositions generally contain heparins having a range of molecular weights, typically from 3 kDa to 40 kDA. Heparin with this wide range of molecular weights is usually referred to as unfractionated heparin (UFH). As currently used commercially, UFH typically has molecular weights in the range 5.0 to 40 kDa.
- In recent years there has been significant interest in the production and use of low molecular weight heparin (LMWH), i.e. a material containing heparin, but of low molecular weight, typically less than 8 kDa, especially heparins in which at least 60 mol % have a molecular weight below 8 kDa. LMWH has a potency of at least 70 units/mg of anti-factor Xa activity and a ratio of anti-factor Xa activity to anti-factor IIa activity of at least 1.5.
- LMWH can be produced from native unfractionated heparin by a variety of processes, e.g. by fractionation or depolymerisation by chemical or enzymatic cleavage, e.g. by nitrous acid depolymerisation, oxidative depolymerisation with hydrogen peroxide, deaminative cleavage with isoamyl nitrite, alkaline beta-eliminative cleavage of the benzyl ester of heparin, oxidative depolymerisation with Cu2+ and hydrogen peroxide or by heparinase digestion.
- There has also been increased interest in synthetic production of very low molecular weight heparin (VLMWH). We have previously shown that heparin extracted from marine animals, in particular fish, naturally has a high content of LMWH and surprisingly also of very low molecular weight heparin (VLMWH), i.e. heparin having a molecular weight less than 3 kDa (see WO 2006/120425, the contents of which are hereby incorporated by reference).
- There is a growing concern about the use of GAGs from mammalian sources in view of the perceived potential for cross-species viral and prion infection. Marine GAGs (e.g. heparin extracted from marine animals) thus provides an alternative. The extraction of marine heparin is described in WO 02/076475, the contents of which are hereby incorporated by reference.
- Previous methods for extracting GAGs from marine material include ion exchange chromatography, electrophoretic separation, sequential precipitation in various organic solvents and various other methods, including those described in the prior art for extraction from animal sources. Many of these techniques are time consuming and inefficient, thus there exists a need for alternative processes for the production of GAGs of marine origin. For example, AT-Sepharose chromatography purifies only the high affinity parts of heparin, whereas, the Applicant has found, conventional bead-based ion exchange systems may also bind unwanted compounds such as lipids. Moreover, in these known techniques, washing must be performed for an extended period of time and high volumes of buffer solutions are required in order to elute the GAGs from the columns (this makes further processing laborious). This leads to problems such as oxidation, precipitation and lack of activity.
- The Applicant has further identified that existing methods for extraction of GAGs from marine animal material may suffer from problems such as unfeasibly long processing times (i.e. up to several days, which can result in release of the odour of decaying fish waste) and low total activity of the resulting product.
- Therefore, in view of the above-mentioned advantages of marine heparins, but the problems associated with current extraction methods, there exists a need for alternative processes for the production of GAGs of marine origin. We have surprisingly found that chromatography using a chromatographic matrix, for example, using a membrane adsorber, particularly an anion exchange membrane adsorber, in extraction of GAGs from non-mammalian marine animal material provides a convenient alternative to conventional extraction techniques. The technique is easy to scale up and automate and it has been surprisingly found that products with outstanding purity and high activity can be produced simply and efficiently.
- Thus viewed from one aspect the invention provides a process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing non-mammalian marine animal material to chromatography using a chromatographic matrix, preferably in the form of a membrane adsorber.
- Viewed for a further aspect, the invention provides a process for extracting glycosaminoglycans from glycosaminoglycan-containing non-mammalian marine animal material said method comprising homogenising said animal material and subjecting the homogenate to chromatography using a chromatographic matrix, preferably in the form of a membrane adsorber.
- In a preferred aspect, the homogenate is repeatedly applied to the chromatographic matrix.
- Preferably, the chromatographic matrix is a membrane adsorber. Membrane adsorbers offer an alternative to traditional bead-based chromatography columns. They are typically based on a chemically stable cellulosic membrane to which a variety of chromatography ligands can be covalently bound. The membrane typically achieves separation by reversible binding of the target molecules to the ligand via their functional groups in a manner analogous to ion exchange chromatography. Typical ligands types are strong/weak anion or cation exchange ligands, metal chelates, epoxy and aldehyde ligands.
- Cationic exchange membranes comprise ligands which contain anionic function groups such as —SO3 −, —OPO3 − and —COO−, e.g. carboxymethyl (CM), sulphopropoyl (SP) and methyl sulphonate (S). Anionic exchange membranes typically contain ligands with cationic functional groups such as —NHR2 + and —NR3 +, e.g. diethylaminoethyl (DEAE), quaternary aminoethyl (QAE) and quaternary ammonium (Q). Quaternary ammonium (Q) is particularly preferred for use in the present invention.
- Membrane adsorbers are macroporous and their major kinetic effect is believed to be convective flow and rapid film diffusion. The adsorbers allow large flow rate ranges without the diffusion limitations found with conventional chromatographic bead/resins etc.
- Membrane adsorbers can be used in a variety of chromatographic applications. Current uses are for the removal of DNA, viruses and endotoxins from pharmaceutical proteins and the purification of viruses, proteins and peptides from solutions. The advantages achieved by the application of this technique to polysaccharides have not previously been appreciated.
- Single use, disposable membrane adsorbers are available, as are membranes which can be reused after suitable treatment. Suitable systems for use in the process of the invention are the Sartobind Membrane Adsorbers available from Sartorius (e.g. Sartobind Anion Direct). The use of a membrane adsorber according to the invention removes the requirement for costly and time consuming column packing and cleaning validation associated with bead-based chromatography systems. It also allows the required number and volume of buffers to be minimised. Use of membrane adsorbers in chromatography allows the process time and buffer usage to be reduced. The adsorbers allow large flow rate ranges and have high binding capacities. Their open structures allows a wide-range of volumes, flow-rates etc. to be used and provide a large surface area for sample/ligand interaction.
- The process of the invention may be a batch process or a column process. The variety of bed-volumes allows the technique to be highly flexible and easy to scale-up. The high volume throughput obtainable with membrane adsorbers makes the process of the invention highly productive compared with conventional methods.
- Preferably the homogenate is extracted from the waste from animal material, e.g. a non-mammalian marine animal after removal of muscle tissue, e.g. for use as a human foodstuff.
- By non-mammalian marine animal material is included material derived from fresh-water as well as salt-water fish, shellfish and crustaceans, such as krill.
- Non-mammalian marine animals used as food sources for mammals or as raw materials for fish meal, fish food, and fish oil are preferred. Particularly preferably, farmed non-mammalian marine animals are used.
- Examples of suitable non-mammalian marine animals include: prawns, shrimp, krill, carp, barbell and other cyprinids; cod, hake, haddock; flounder; halibut; sole; herring; sardine; anchovy; jack; mullet; saury; mackerel; snoek; cutlass fish; red fish; bass; eels (e.g. river eels, conger, etc.); paddle fish; tilapia and other cichlids; tuna; bonito; bill fishes; diadromous fish; etc. Particular examples of suitable fish include: flounder, halibut, sole, cod, hake, haddock, bass, jack, mullet, saury, herring, sardine, anchovy, tuna, bonito, bill fish, mackerel, snoek, shark, ray, capelin, sprat, brisling, bream, ling, wolf fish, salmon, trout, coho and chinock. Especially preferably the non-mammalian marine animal used is trout, salmon, cod or herring, more especially salmon or hill. Krill are particularly preferred, for example Antarctic hill (Euphausia superba), Pacific krill (Euphausia pacifica) and Northern krill (Meganyctiphanes norvegica).
- The glycosaminoglycan-containing non-mammalian marine animal waste used as the source for heparin extraction will typically be selected from heads, skin, gills, and internal organs. The use of gills alone, of heads and of internal organs is especially preferred. Methods of processing fish waste are known from the literature, e.g. WO2004/049818.
- The homogenate of the animal material can be prepared by standard methods, e.g. physical or chemical pretreatment, e.g. maceration, acid or base treatment, etc., in particular grinding or blending.
- The homogenate may be further treated in order to remove particulate material, for example via centrifugation and/or filtration. However, this is not always necessary, for example we have surprisingly found that crude homogenate can be applied directly to the membrane (conventional chromatography generally requires more extensive pre-treatment steps). However, in the process of the invention, the homogenates are preferably centrifuged or otherwise subjected to fines-removal, particularly if the source is fish gill material.
- In an especially preferred embodiment, the homogenate is treated with an enzyme, particularly a protease such as papain in order to digest the proteins present in the homogenate, prior to application to the membrane system. Alternatively, or additionally, the homogenate may be heated to 50 to 200° C., preferably 70 to 120° C., especially preferably, 80 to 100° C., e.g. around 80° C. in order to inactivate the proteins.
- Typically, the pH of the sample should be adjusted such that it is at least 1.0 above or below the isoelectric point of the desired GAG (for anion- or cation-exchange respectively). Anion exchange is preferred for the GAG extraction of the present invention, in which case a pH of around 5 is preferred.
- The pH of the membrane may be stabilized prior to sample application, for example by using an equilibrium buffer. Equilibrium buffers (and other conditions and methods) used in standard chromatographic separation techniques may be used in the process of the invention. For example, for anion exchange, suitable buffers (which may include a salt, such as NaCl) are NH4Ac/HAc, Bis-Tris/HCl and citrate buffer, e.g. 5 mM NH4Ac/HAc, 10 mM NaCl/25 mM NH4Ac/HAc, 10 mM NaCl/25 mM Bis-Tris/HCl and 10 mM NaCl/25 mM citrate buffer. Suitable equilibration buffers for use in the invention when a cation exchange membrane is utilised are; citrate, formate, acetate, malonate, MES, phosphate etc.
- For anion exchange, the pH of the equilibrium buffer will be 4.5 to 10, preferably 5 to 6.5, e.g. around 5.5. For cation exchange, much lower pHs are required, e.g. 1 to 4, preferably around 2.
- The method of the present invention enables the sample (homogenate) to be recirculated, and thus the exposure of the sample to the matrix can be controlled. Said recirculation can be achieved in any convenient manner, for example by positioning the inlet and outlet tubings in the same vessel. The homogenate can therefore be repeatedly applied to the chromatographic matrix. Preferably the homogenate is repeatedly applied to the matrix (e.g. the membrane adsorber) by recirculating the homogenate. That is, the flow-through (i.e. any material not bound to the matrix) is reapplied to the matrix, preferably immediately following it leaving the membrane adsorber (i.e. before elution of eluate). Especially preferably the homogenate is recirculated, i.e. repeatedly applied to the matrix for several minutes (e.g. up to 4 hours) before the bound compounds are eluted. Typical application times are 5 minutes to 3 hours, preferably 15 minutes to 2 hours, more preferably 30 minutes to 1.5 hours, especially preferably 45 minutes to 1 hour. A typical residence time for a 2.5 ml membrane in recirculation mode for 30 minutes is around 2.8 s.
- Thus, viewed from a further aspect, the present invention provides a process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing non-mammalian marine animal material to chromatography using a chromatographic matrix, wherein said homogenate is repeatedly applied to said matrix. In this embodiment, the matrix is preferably in the form of a membrane adsorber as herein described.
- After the sample has been applied to the membrane, whether by a single pass or by using recirculation as described above, the bound GAG compounds can be eluted. Elution may be effected using step-wise increases in ionic strength and/or changes in pH, or a suitable gradient. Preferably, elution is carried out using a suitable elution buffer. Clearly these will depend on the nature of the stationary phase. For anion exchange, the pH of the elution buffer will be 4.5 to 10, preferably 5 to 6.5, e.g. around 5.5.
- Suitable elution buffers for use in anion exchange methods according to the invention are those in which the concentration of the mobile phase counter ion is increased. This is conveniently effected by adding NaCl to the equilibrium buffer. 1-15M, preferably 2-20M, e.g. 3-4M NaCl is typically used for anion exchange methods e.g. buffers such as 1-4 M NaCl in 5 mM NH4Ac/HAc, 3 M NaCl in 25 mM NH4Ac/HAc, 10 mM NaCl in 25 mM citrate buffer, 3.5 M NaCl/5 mM citrate buffer. Suitable elution buffers for use in the invention when a cation exchange membrane is utilised are; citrate, formate, acetate, malonate, MES, phosphate. In both cases the pHs are similar to those outlined for the equilibrium buffers above.
- The GAG-containing composition of the process may be concentrated, desalted and/or dried before further handing. Freeze drying is preferred. In a preferred embodiment, the eluate is desalted, e.g. using a Millipore/Amicon stirred cell with a Nanomax-50 filter, and then freeze-dried. This is particularly useful if the unfractionated product (UFH) is to be fractionated as it removes the salt and minimizes the volume of the redissolved sample to be applied to a size exclusion chromatography (SEC) column, e.g. a G-75 Sephadex column.
- The membrane can be reused after elution, by washing in a suitable buffer solution such that the membrane is regenerated.
- Moreover, the flow-through (i.e. the material which has been applied to the membrane, whether by a single application or using recirculation, but did not bind) can be reapplied to the membrane after the elution step. In this way, the same homogenate can be used until all substantially of the desired GAG has been isolated.
- In a further aspect of the invention, more than one membrane adsorber can be used, these can be arranged in series or parallel.
- Membrane capacities can be chosen according to the size of the sample, and thus the method is easy to scale up. Typical bed volumes are in the range of from 5 to 2500 ml, whereas membrane areas are typically from 200 cm3 to 10 m3.
- The invention allows use of higher flow rates than conventional ion chromatography. These will depend on the capacity of the membrane. Typical flow rates for a 2.5 ml membrane are, 5 to 60 ml/min, especially 10 to 50 ml, especially preferably 20 to 40 ml/min, for example around 30 ml/min.
- Recirculation time and flow rate can be adjusted according to requirements. The total amount of sample exposed to the matrix is the product of recirculation time and flow rate.
- The degree of exposure of the sample to the membrane is defined as (recirculation time×flow rate)/matrix volume. For example, recirculating at 25 ml/min for 1 hour, results in a volume of 1500 ml being exposed to the matrix (60 min×25 ml/min). For a 2.5 ml membrane, this equates to a degree of exposure value of 600 (i.e. 600 ml per ml of membrane). Preferably, the degree of exposure as defined herein is from 50 to 3000, preferably 200 to 1000, especially 400 to 800, more especially 500 to 700, particularly around 600.
- At any stage in the process of the invention, antioxidants may be used in order to avoid any unwanted decomposition.
- Typical membrane binding capacities (cm3) are >0.8 mg BSA on strong anion, >0.8 mg lysozyme on strong cation.
- Typical static binding capacities (mg/device volume) are >72 mg/2.5 ml, >720 mg/25 ml, >7200 mg/250 ml;
- The ion capacity (cm3) is usually around 4-6μ equiv.
- Preferably the feed stream is routed tangentially over the membrane layers which are separated by a spacer.
- The glycosaminoglycan (GAG) extracted by the process of the invention are preferably glucosaminoglycans, especially those with anticoagulant properties, particularly heparin, a heparinoid, or a low molecular weight heparin or heparinoid, or a mixture of two or more thereof. Preferably it is a sulphated GAG, in particular a heparin or LMWH, especially preferably it is a high affinity GAG.
- By “anticoagulant” it is meant that a GAG has the ability to bind to antithrombin, an inter-alpha-trypsin inhibitor, factor Xa, and other proteins to which mammalian heparin binds, e.g. immobilized on a substrate such as a gel matrix, and/or the ability to delay or prevent clotting in human plasma or to prolong bleeding in a mammal (e.g. a mouse).
- Glycosaminoglycans, particularly anticoagulant glycosaminoglycan or glucosaminoglycans, especially preferably heparins extracted from krill, are in themselves novel and inventive and thus form a further aspect of the present invention. Preferably these glycosaminoglycans are extracted via the processes described herein, however any suitable extraction method may be used, for example those set out in WO 02/076475 and WO 2006/120425.
- Both the krill GAG products mentioned above and the products of the process of the invention constitute a further aspect of the invention. These products may be further processed, for example the resulting UFH compositions may be treated (e.g. fractionated or depolymerized) to give compositions enriched or depleted in LMWH and/or VLMWH etc. The fractions, and compositions enriched or depleted in them, form a further aspect of the present invention.
- The products of the invention may be used according to the invention in its naturally occurring form following extraction, for example as UFH. However alternatively it may be converted into salt form, preferably with a physiologically tolerable counterion (e.g. sodium, calcium, magnesium, potassium, ammonium or meglumine), or derivatised, e.g. to facilitate its binding to a surface of an item of medical apparatus, or molecular weight fractionated or depolymerised (e.g. to produce a GAG fraction meeting the molecular weight definition for LMWH). As with the products of the processes herein described, such derivatives are preferably physiologically tolerable.
- Preferably, the product of the chromatographic process is then fractionated and/or depolymerised.
- Preferably, fractionation is achieved by filtration (e.g. membrane filtration) or chromatographically, especially preferably using size exclusion chromatography, ion exchange chromatography, or sample displacement chromatography. Suitable methods are set out in WO 2006/120425.
- In a preferred embodiment of the invention the marine GAG composition is concentrated and desalted before further processing such as fractionation.
- Especially preferably the marine GAGs of the invention are subjected to membrane filtration to remove low molecular weight components, e.g. with a molecular weight before that of the antithrombin binding pentamer (MW 1728 Da), typically using a membrane with a 1 kDa cut-off (e.g. Omega-1k Ultrasette from Filtron/Pall, Millipore Pellicon 1 kDa cut-off). Also especially preferably the marine GAGs are subjected to membrane filtration to remove high molecular weight components, for example with a molecular weight cut-off of 3000 Da (e.g. using Omega Centramate Suspended Screen OS005C11P1 from Filtron/Pall). This enables the production of LMWH- and/or VLMWH-enriched fractions in addition to the UFH product. Such fractions can be used separately, in combination (e.g. in combination therapy) or blended to provide GAG compositions to meet a variety of requirements. For example, the product may be fractionated to produce a fraction enriched in LWMH or VLMWH. The remaining fraction, depleted in either LMWH or VLMWH, may be retained and used alone or added to further unfractionated product. In this way waste of the products is minimised.
- The compositions produced according to the process of the invention and described herein (whether UFH or following the fractionation steps set out above) may be dried or may be formulated for use, e.g. with a diluent, carrier or an active drug substance, and it may be applied, preferably after formulation with a liquid carrier, as a coating to the surface of a medical instrument, e.g. a catheter or implant. Such compositions and coated instruments form further aspects of the present invention, as does the process for their preparation, e.g. by admixing or coating.
- Viewed from a further aspect the invention provides a non-mammalian marine animal glycosaminoglycan composition produced by the processes herein described, optionally further containing a physiologically acceptable carrier or excipient and/or a drug substance and optionally coated onto a substrate. Such compositions for use in medicine or therapy form a further aspect of the present invention.
- Viewed from a further aspect the invention provides a hill glycosaminoglycan composition, optionally further containing a physiologically acceptable carrier or excipient and/or a drug substance and optionally coated onto a substrate. Such compositions for use in medicine or therapy form a further aspect of the present invention.
- Viewed from a still further aspect the invention provides the use of a composition according to the invention or produced according to the process of the invention, or a salt or derivative thereof, in mammalian, especially human, medical treatment, e.g. in compositions or equipment used in surgery, therapy, prophylaxis, or diagnosis on human or non-human animal subjects or for blood contact. In a preferred aspect, the compositions are fractionated (e.g. according to activity or molecular weight) to provide compositions enriched in certain fractions, e.g. VLMWH.
- Viewed from a further aspect the invention provides a pharmaceutical composition comprising hill GAGs or non-mammalian marine animal GAGs produced by the process herein described or a salt or derivative thereof together with a physiologically tolerable carrier or excipient, and optionally also a therapeutic or prophylactic drug substance.
- The GAG compositions according to the invention may further contain non-GAG components conventional in mammalian GAG compositions, e.g. water (preferably water for injections), ethanol, buffers, osmolality adjusting agents, preservatives, etc.
- Besides use as anticoagulants, the GAGs of the invention may be used as antithrombotics, anti-atherosclerotics, complement inhibitors, anti-inflammatories, anti-cancer agents, anti-viral agents, anti-dementia agents (e.g. anti-Alzheimer agents), anti-prion agents, anti-parasitics, opsonization inhibitors, biomaterials, angiogenesis regulators, and in the treatment of vascular deficit, wounds and immune response disorders (e.g. AIDS), etc. They may be administered enterally or parenterally, e.g. orally or subcutaneously or bound to an object or drug material placed into tissue or the circulatory system.
- Besides such therapeutic and surgical uses, the GAGs of the invention may be used for diagnostic purposes, e.g. diagnostics assays, and non-medical uses for which heparin is suited or currently used. Thus viewed from a further aspect the invention provides a diagnostic assay kit comprising an anticoagulant, characterised in that said anticoagulant is a glycosaminoglycan according to the invention.
- The process of the invention has been carried out on mammalian material and has been found to be equally applicable to mammalian material as it is to material of non-mammalian marine animal origin. The glycosaminoglycan-containing mammalian material used as the source for heparin production/extraction according to this aspect of the present invention is preferably waste from meat-processing, i.e. waste following the extraction of material for food. Intestines, preferably bovine or porcine intestines, are thus preferred sources. The above-mentioned processes, products and uses, using mammalian material (preferably non-human mammalian intestinal material) rather than non-mammalian marine animal material, thus form further aspects of the present invention.
- Thus, viewed from a further aspect the present invention provides a process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing mammalian intestines to chromatography using a chromatographic matrix in the form of a membrane adsorber. A process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing mammalian intestines to chromatography using a chromatographic matrix (preferably a membrane adsorber) wherein said homogenate is repeatedly applied to said matrix is also provided.
- Preferably the mammal from which the mammalian material is derived is a non-human mammal. Examples of suitable mammals include cattle, goats, sheep, deer, pigs, swine, boar etc. Bovine and porcine materials are especially preferred.
- Documents referred to herein are hereby incorporated by reference.
- The invention will now be described further with reference to the following non-limiting Examples. In all Examples the pump used was a Pump Masterflex I/P, except for elution where a peristaltic Pharmacia P-1 pump was used. The membrane used was a 2.5 ml Sartobind® Anion Direct, Strong basic anion exchanger membrane.
- A salmon intestine extract was prepared by homogenizing 280 g salmon intestines in Milli-Q water. The theoretical amount of GAG (glycosaminoglycan) as measured by the carbazole method was calculated as 98 mg (N.B. the carbazole test results in a red/violet colour for glycosaminoglycans which contain uronic acid).
- Proteins were degraded by papain at 55° C., then inactivated by heating to 80° C. Coarse particles were removed by filtering through a nylon filter. The extract was then adjusted to pH 5.5 by adding 0.5 M ammonium acetate/acetic acid (pH 5.5) to 25 mM (final concentration of acetate) and NaCl (final concentration of 10 mM). The pH was measured as 6.08.
- Elution 1: The resulting extract was then recirculated (by immersing the inlet and outlet of the tubing in the same beaker) on a the membrane at around 25 ml/min for 64 minutes and then washed with 150-200 ml of the equilibration buffer (25 mM acetate/acetic acid/10 mM NaCl, pH 5.5). Elution was then carried out using 20 ml 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (Eluate no. 1).
- Elution 2: The membrane was then washed with equilibration buffer and the extract (i.e. the flow-through from Elution 1) was applied again, this time for 45 min. It was washed with equilibration buffer (150-200 ml) and allowed to stand overnight. Elution was then carried out using 20 ml 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (Eluate no. 2).
- Elution 3: The membrane allowed to stand in 1 M NaOH for around 1 hour and was then washed with equilibration buffer. The extract (i.e. the flow-through from Elution 2) was applied again for 55 min, washed with equilibration buffer, then eluted in 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (Eluate No. 3).
- Elution 4: The membrane allowed to stand with 1 M NaOH for around 1 hour and was then washed with equilibration buffer. The extract (i.e. the flow-through from Elution 3) was applied again for 51 min, washed with equilibration buffer, then eluted in 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (Eluate No. 4).
- Elution 5: The equilibration buffer was then changed to 25 mM NH4Ac/HAc, pH 5.0/10 mM NaCl and pH in the extract (i.e. the flow-through from Elution 4) adjusted to 4.96 (using 6 M HCl). This was circulated on the membrane for 60 min, and the membrane was then washed with 200 ml of the equilibration buffer. Eluate no. 5 was obtained using 20 ml 3 M NaCl in 25 mM NH4Ac/HAc, pH 5.0.
- Elution 6: The pH of the extract (i.e. the flow-through from Elution 5) was then adjusted to 5.5 (using 3M NaOH), and the membrane was washed with in 25 mM NH4Ac/HAc, pH 5.5/10 mM NaCl. The extract was recirculated on the membrane for 60 minutes. Eluate no. 6 was obtained using 3 M NaCl (20 ml) in 5 mM NH4Ac/HAc, pH 5.5.
- Elution 7: The membrane was kept in 20% EtOH in equilibration buffer overnight and then treated with 1 M NaOH for around 45 minutes, then washed. The extract (i.e. the flow-through from Elution 6) was recirculated for 60 minutes on the membrane. Eluate no. 7 was obtained using 3 M NaCl (20 ml) in 5 mM NH4Ac/HAc, pH 5.5.
- The results are summarised in the following table:
-
Eluate Weight of Concentration of volume heparin in heparin in eluate Eluate (ml) eluate (mg) (mg/ml) Comments 1 14.2 0.794 0.0559 Carbazole test gave a brownish colour 2 19.0 0.974 0.0513 pH 6.06 in extract 3 19.0 0.706 0.0372 Yellow/brown in test 4 18.9 1.635 0.0171 5 20.3 0.210 0.0103 pH 5.0 in extract 6 15.5 0.722 0.0460 pH 5.5 in extract 7 18.9 2.074 0.1097 Yellow in test Sum 7.12 - The pooled eluates (i.e. Eluates 1 to 7 are combined) were concentrated and desalted for biological tests.
- The salmon homogenate that had been passed 7 times on the membrane (i.e. the flow-through from Elution 7 of Example 1) was kept at +4° C. and pH was adjusted to 6.0 with Bis-Tris (i.e. Bis(2-hydroxyethyl)amino-Tris(Hydroxy-methyl)methane). The membrane was washed 3 times with 1 M NaOH (with buffer washings of 25 mM Bis-Tris/HCl/10 mM NaCl, pH 6.0 in-between) and then equilibrated with 25 mM Bis-Tris/HCl/10 mM NaCl, pH 6.0 (the equilibration buffer).
- The homogenate was recirculated on the membrane at room temperature for 60 minutes at a flow rate of 25 ml/min. The in/out tubings were in the same beaker, as in Example 1, with the inlet at the bottom and the outlet on the top. After washing with the equilibration buffer, elution was carried out using 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (as previously). The volume of the eluate was 24.4 ml.
- The total amount of uronic acid-containing GAG as measured by the carbazole test was 0.933 mg.
- The combined eluates (1 to 7) from Example 1 were concentrated and desalted on a Millipore Pellicon 1000 MWCO membrane using tangential flow. The sample (i.e. everything from the eluates of Example 1 which has a molecular weight above 1000 Da) was then freeze-dried. The white, powder-like residue obtained had a weight of 630 mg.
- An aliquot of freeze-dried eluate was tested for heparin activity in a thrombin/antithrombin assay using a colorimetric thrombin substrate. This test revealed a strong heparin activity. A further aliquot of the freeze-dried eluate was analysed for quantitative heparin activity determination. The 21.5 mg aliquot gave 0.26 U/ml (dissolved in 1 ml). This equals a total of 7.62 U in 630 mg.
- The homogenate that had been passed 8 times on the membrane (i.e. the flow-through from Example 2) was recirculated again on the membrane for 1 hour (following storage for four days in a refrigerator) using a flow rate of 25 ml/min. The homogenate was then washed with equilibration buffer (25 mM Bis-Tris, pH 6.0/10 mM NaCl). Elution was performed using 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (as previously).
- The carbazole test gave 3.02 mg total in the eluate. The eluate was desalted and concentrated as described in Example 3.
- A salmon gill extract was made by homogenizing 444.4 g salmon gills (the gills were cut out, leaving the cartilage, gristle) in Milli-Q water. Proteins were degraded by papain at 55° C., then inactivated by heating to 80° C. Coarse particles were removed by filtering through a nylon filter. The pH in the homogenate was measured to 6.81, this was adjusted using 6 M HCl to 6.0.
- The homogenate was centrifuged (12,000 rpm for 30 minutes). The supernatant was saved and, prior to each elution step was recirculated on the membrane for 60 minutes using a flow rate of 25 ml/min.
- Elution 1: Washing and elution (Eluate no. 1) was carried out with 3 M NaCl/5 mM Bis-Tris, pH 6.0.
- Elution 2: The membrane was treated with 1 M NaOH for 45 minutes before the next recirculation (of the flow-through from Elution 1), washing and elution were carried out as described above (Eluate no. 2).
- Elution 3: The membrane was then treated with 1 M NaOH overnight, followed by recirculation of the flow-through from Elution 2, washing and elution as described above (Eluate no. 3).
- The amount of uronic acid-containing glucosaminoglycan was determined using the carbazole test in triplicate for each eluate:
-
Eluate Weight of uronic acid-containing GAG (mg) 1 8.6 2 6.2 3 5.6 - The pooled extracts (eluates 1 to 3) were desalted, concentrated and freeze-dried (as described in Example 5). The weight of the freeze-dried sample was around 61 mg. The freeze-dried eluate was a white, fluffy powder. An activity test gave a total of 2.56 U in 61 mg.
- The flow-through of the homogenate after eluates 1, 2, 3 was recirculated on the membrane 6-7 days after the first round (i.e. after elutions 1, 2 and 3).
- Eluates 4, 5 and 6 were obtained as above. The membrane was treated with 1 M NaOH 45 minutes after eluate 5. The results are given in the following table:
-
Weight of uronic acid-containing GAG as measured by Eluate the carbazole test (mg) 4 7.4 5 11.2 6 7.4 - The pooled eluates (4 to 6) were desalted, concentrated and freeze-dried. The membrane was then equilibrated using 25 mM Bis-Tris/10 mM NaCl, pH 6.0 and the flow-through from Elution 6 was recirculated on the membrane for 1 hour using a flow rate of 25 ml/min and eluted using 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5 (Eluate 7). The homogenate (i.e. the flow-through from Eluate 7) was then adjusted to pH 7.0 using 4 M NH3. The membrane was equilibrated using NH4Ac/HAc, pH 7.0. and the homogenate was recirculated on the membrane for 1 hour using a flow rate of 25 ml/min, then eluted as above (Eluate 8). The results of the carbazole test of Eluates 7 and 8 are shown below:
-
Weight of uronic acid-containing GAG as measured by Eluate the carbazole test (mg) 7 5.6 8 6.4 - The pool of intestine extracts (i.e. the combined eluates 1 to 7 from Example 1) was concentrated and desalted on Millipore Pellicon 0.5 m2 1000 MWCO-membrane (tangential flow), then freeze-dried. The resulting freeze dried sample has a weight of around 630 mg, an aliquot of 21.5 mg was submitted to activity testing at the Central Laboratory, Aker University Hospital, Norway.
- Analysis showed a total activity of 0.26 U, i.e. 12 U/g and 7.6 U from the whole batch. The carbazole test gave 7.12 mg total which gives 1.07 U/mg.
- Two pools of eluate from gill homogenate eluate (from Example 7), i.e. pool of eluates 1, 2, 3 and pool of eluates 4, 5, 6 were desalted and concentrated in an Amicon stirred cell w/1000 MWCO-filter.
- Analysis showed Eluate 1, 2, 3 to have an activity of 0.21 U in 5.0 mg, i.e. 0.042 U/mg.
- Total: 2.56 U in 61 mg, i.e. 0.042 U/mg (by weight).
After carbazole-test: 2.56 U in 20.4 mg (0.125 U/mg) - Analysis showed Eluate 4, 5, 6 to have an activity of 0.11 U in 2.4 mg.
- Total: 1.12 U in 24.5 mg, i.e. 0.046 U/mg (by weight).
After carbazole-test: 1.12 U in 26 mg (0.043 U/mg). - The eluate from Example 6 (i.e. that from intestine homogenate of Example 3 and kept in fridge when not in use) was desalted and concentrated in Amicon stirred cell with 1000 MWCO, total weight: 0.269 g, aliquot to test: 0.020 g.
- Result: 0.23 U/ml, i.e. 3.09 U total (0.0114 U/mg).
- Eluates 7 and 8 from Example 5 and the flow-through from Eluate 8 were concentrated and desalted in Amicon stirred cell and gave a total weight of 0.091 g.
- An aliquot of 0.0023 g was submitted for testing and gave 0.1 U/ml.
- Total activity: 3.95 U, i.e. 0.0434 U/mg.
- Fractionated eluate on Sephadex G75 (from Example 3)<8000, conc. and desalted in Amicon stirred cell gave a total weight of 0.161 g.
- An aliquot of 0.0118 g gave 0.12 U/ml.
Total activity: 1.64 U, i.e. 0.010 U/mg. - >8000 pool from the Sephadex G 75 fractionation above was concentrated and desalted in Amicon stirred cell resulting in a total weight of 0.030 g. An aliquot of 0.0008 g gave 0.53 U/ml, i.e. 19.88 U total. This corresponds to 0.663 U/mg.
- An extract from salmon intestines (498 g, stored at −20° C.) was made by homogenizing the salmon intestines in 498 ml Milli-Q water, using a Braun handheld homogenizer for a few minutes. Protein digestion was carried out at 55° C. for 3 hours, using 0.5 g papain, followed by inactivation at 80° C. for 1 hour.
- After cooling to room temperature, the homogenate was filtered through a nylon filter, removing the course particles. The pH of the filtrate was adjusted to 6.2 using 0.5 M citrate buffer, pH 6.2. The final volume was 1000 ml which was divided into 5 aliquots of 200 ml and kept at +4° C. when not in use.
- The membrane was treated with 1 M NaOH for 1 hour between every use. The equilibration buffer was 25 mM citrate buffer, pH 6.2/10 mM NaCl in all experiments described in this Example. In each case elution was performed using 25 mM citrate buffer, pH 6.2/10 mM NaCl.
- After equilibration with the buffer, the homogenate was recirculated for the given period of time, then washed with ca. 100-120 ml of the equilibration buffer and eluted.
- The amount of glycosaminoglycan (GAG) was determined by measuring the volume of the eluates and performing the carbazole test using 3-4 aliquots of 3 μl (12 μg) unfractionated porcine heparin for standard and 3-7 aliquots (200 μl) of the eluates.
- Different aliquots of the homogenate was used for each experiment. The inlet and outlet of the homogenate was in the same beaker. The recirculation speed was 22 ml/min. The elution speed was 1.4 ml/min. The results are shown in the following table:
-
Recirculation time total amount of GAG (mg) 45 minutes 1.683 1 hour 2.860 2 hours 2.314 5 hours 1.935 - In a further experiment the recirculation speed was 9.7 ml/min, using the Pharmacia P-1 pump and the last 200 ml aliquot of the homogenate. Recirculation was performed for 1 hour and elution speed was as above. The total amount of GAG detected was 1.843 mg.
- The 5 aliquots used in Example 7 were pooled, mixed and divided into 5 equal aliquots. The contents of aliquot 1 were centrifuged at 12 000 rpm (23 975×g) for 30 minutes. The supernatant was pipetted off, taking care to avoid the lipid layer and the precipitate.
- This supernatant was then recirculated (22 ml/min) on the Sartobind Anion Direct membrane for 1 hour. The membrane was equilibrated against 25 mM citrate buffer pH 6.2/10 mM NaCl. After recirculation, the membrane was washed with the equilibration buffer (110-120 ml) and eluted using 20 ml 3.5 M NaCl in 5 mM citrate buffer pH 6.2. The membrane was incubated with 1 M NaOH for 1 hour, then washed against the pH 6.2 equilibration buffer.
- An aliquot (not centrifuged) was then allowed to recirculate on the membrane for 1 hour. Washing and elution was performed as above.
- The volume and amount of GAG (carbazole-test) was determined:
-
Sample Amount GAG (mg) Centrifuged homogenate 4.173 non-centrifuged homogenate 4.377 - This Example shows that untreated, crude homogenate from intestines can be applied onto the membrane adsorber in the process of the invention. In contrast, the homogenate from gills should ideally be centrifuged or otherwise subjected to fines-removal.
- Thus, a further advantage of this method is that crude or fines-filtrated homogenate can be applied, while conventional anion chromatography requires a more extensive centrifugation or filtration.
- The effect of pH was also investigated. The pH was checked in a 3rd homogenate-aliquot and found to be 6.73, in spite of the pH-adjustment in Example 9. The pH in this aliquot was adjusted to 5.5 using solid citric acid. The membrane was equilibrated with 25 mM citrate buffer pH 5.5/10 mM NaCl. The homogenate was recirculated (22 ml/min) for 1 hour, washed (110-120 ml) and eluted using 3.5 M NaCl/5 mM citrate buffer, pH 5.5.
- Volume and amount of GAG (carbazole-test) was determined and compared in parallel to previous eluates from 1 hour recirculation (Example 7).
-
Sample amount GAG (mg) Eluate pH 5.5 2.209* Eluate pH 6.2 3.115 Eluate pH 6.2 3.434* - The pH 5.5-eluate appears to give a lower yield, however, it gave a purer product than the pH 6.2-eluates.
- An aliquot of 0.0287 g of the pH 5.5 eluate above and an aliquot of 0.0571 g of the second pH 6.2 eluate of the above table was tested for anti factor Xa activity at Aker university hospital and gave a total of 1.8 U and 3.1 U, respectively. This gives the following specific activities:
- which indicates an advantage in the use of pH 5.5 elution.
- The remaining two aliquots from Example 7 were used. The speed of recirculation was calibrated to 44 ml/min. The equilibration buffer was 25 mM citrate buffer, pH 6.2/10 mM NaCl, the elution buffer was 3.5 M NaCl in 5 mM citrate buffer, pH 6.2. The elution speed was 1.4 ml/min (as in Example 7). The pH of the two homogenates was adjusted to 6.2 using solid citric acid.
- In the first experiment, recirculation was allowed for 1 hour, then washed with 110-120 ml equilibration buffer and finally eluted. In the second experiment, recirculation was allowed for 30 minutes, then treated as above.
- The volume and GAG-content (carbazole-test, 4×200 μl samples of eluate and 4×3 μl of standard) was determined in the two eluates.
-
Recirculation time Amount GAG (mg) 30 min 1.854 60 min 1.787 - As the difference is probably within the error of the method, both recirculation times give similar yields. Taken together with previous results (Example 7), similar yield can be obtained if the recirculation time is reduced to 30 minutes from 60 minutes and the speed of recirculation increased from 22 ml/min to 44 ml/min.
- The remains of the salmon intestine homogenate from Example 7 were pooled and divided into 5 aliquots of 189 ml and kept at +4° C. until use. Aliquot no. 1 was taken out, the pH adjusted to pH 5.5 using solid citric acid. This was recirculated on the equilibrated (25 mM citrate buffer, pH 5.5/10 mM NaCl) Sartobind Direct Anion membrane for 1 hour at 25° C. and with a pump (MasterFlex I/P) speed of 22 ml/min. The membrane was washed with 110-120 ml of the equilibration buffer. Elution was performed using 3.5 M NaCl/5 mM citrate buffer, pH 5.5 (20 ml).
- Aliquot no. 2 was taken out and the pH adjusted as above. The aliquot was kept in a water bath and the temperature on the membrane was measured to 34° C. during recirculation. Apart from the temperature, the experiment was performed as above.
- Aliquot no. 3 was taken out and pH adjusted as above. The aliquot was kept in a water bath and the temperature on the membrane was measured to 41° C. Apart from the temperature, the experiment was performed as above.
- Aliquot no. 4 was taken out and pH adjusted as above. Recirculation on the Sartobind membrane was carried out at 27° C. and the experiment performed as above.
- Elution was performed using first 20 ml 50 mM citrate buffer, pH 2.8, followed by 20 ml 500 mM citrate buffer, pH 2.8, in separate eluates.
- The GAG content was determined using the carbazole test. The precise volume of the eluates (ca. 20 ml each) were determined as set out in the following table.
-
Eluate total amount of GAG (mg) pH 5.5/25° C. 4.438 pH 5.5/34° C. 2.703 pH 5.5/41° C. 3.324 50 mM pH 2.8/27° C. 0.611 500 mM pH 2.8/27° C. 1.663 Sum pH 2.8 eluates 2.274 - There does not appear to be an increase in the yield at higher temperature. Two eluates were submitted for activity testing and specific activity determination (eluates at pH 5.5 and pH 6.2).
- The last aliquot from Example 10 was recirculated on the membrane by keeping the inlet and the outlet tubing in separate beakers. The complete contents of the outlet beaker was transferred to the inlet beaker once this was emptied. This was performed for 1 hour (effective time) at 27° C. at the speed of 22 ml/min. The membrane was calibrated with 25 mM citrate buffer, pH 5.5/10 mM NaCl. The pH of the aliquot was adjusted to 5.5 before its use.
- Elution was performed using 3.5 M NaCl/5 mM citrate buffer, pH 5.5. This eluate was compared to the 25° C. sample from Example 10. All samples were tested in quadruple (200 μl from the eluates and 3 μl from the standard, as usual in these Examples, unless otherwise noted).
-
Eluate total amount of GAG (mg) Inlet and outlet in different beakers 1.654 Inlet and outlet in same beaker 1.725 - The results are comparable and the method has the advantage that the inlet and outlet tubing may be kept in the same beaker. This avoids transferring the contents in order to allow recirculation.
- Equal amounts of krill tissue and buffer (5 mM NH4CO3/NH3 in 0.1 M NaCl, pH 9.0) or Milli-Q water are homogenized in a tissue grinder (kitchen utility type, Braun). Typically, 300 g tissue in 300 ml buffer/water is used. The homogenate is incubated 55° C. with 0.3 g papain for 3 hours and then at 80° C. for 1 hour and centrifuged at 13000 rpm. The supernatant is applied onto a Dowex (2×8, anion exchanger), which is equilibrated in the buffer above and washed with the same buffer. Glycosaminoglycans are eluted using 4 M NaCl in the same buffer. This eluate is concentrated and desalted in a stirred cell (Amicon 8400) with a Nanomax-50 filter (MW cut-off=1000 Da). The concentrated and desalted eluate is freeze dried.
- A krill extract is made by homogenizing 400 g frozen krill in Milli-Q water. Proteins are degraded by papain at 55° C., then inactivated by heating to 80° C. Coarse particles are removed by filtering through a nylon filter. The pH in the homogenate is adjusted using 6 M HCl to 6.0. The homogenate is centrifuged (12,000 rpm for 30 minutes). The resulting extract is then recirculated (by immersing the inlet and outlet of the tubing in the same beaker) on a Sartobind® Anion Direct, Strong basic anion exchanger membrane at 25 ml/min for 60 minutes and then washed with 200 ml of equilibration buffer (25 mM acetate/acetic acid/10 mM NaCl, pH 5.5). Elution is then carried out using 20 ml 3 M NaCl in 5 mM NH4Ac/HAc, pH 5.5. Further elutions are carried out as stated above. The amount of uronic acid-containing glycosaminoglycan is determined using the carbazole test.
- Pig intestines were collected fresh from slaughter and kept on ice. The intestines were emptied of their contents and washed in tap water. 444 g of washed intestines were added to 444 ml of Milli-Q water and homogenized. Proteins were degraded by using papain at 55° C. for 3 hours, then inactivated at 80° C. for 1 hour. Coarse particles were removed by filtering through a nylon filter. The extract was then added to 0.5 M ammonium acetate/acetic acid (pH 5.5) to 25 mM (final concentration of acetate) and NaCl (final concentration of 10 mM). The pH was adjusted to 5.50 by adding 50% (v/v) acetic acid.
- Purification: The resulting extract was then recirculated (by immersing the inlet and outlet of the tubing in the same beaker) on a membrane at around 25 ml/min for 45 minutes and then washed with 150-200 ml of the equilibration buffer (25 mM acetate/acetic acid/10 mM NaCl, pH 5.5). Elution was then carried out using 20 ml 4 M NaCl in 5 mM NH4Ac/HAc, pH 5.5. The total amount of glycosaminoglycan in the eluate was determined as 0.515 mg using the carbazole test. The eluate was desalted and concentrated in an Athicon stirred cell w/1000 MWCO-filter. The freeze-dried eluate was tested for heparin activity at the Clinical Chemistry Core Unit, Aker University Hospital using the Stachrom Heparin Diagnostica assay. This gave a total of 3.7 antifactor Xa units.
Claims (16)
1. A process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing non-mammalian marine animal material to chromatography using a chromatographic matrix in the form of a membrane adsorber.
2. A process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing non-mammalian marine animal material to chromatography using a chromatographic matrix, wherein said homogenate is repeatedly applied to said matrix.
3. The process claimed in claim 1 or claim 2 wherein said non-mammalian marine animal material is krill material.
4. The process claimed in claim 1 or claim 2 wherein said non-mammalian marine animal material is salmon material.
5. A process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing mammalian intestines to chromatography using a chromatographic matrix in the form of a membrane adsorber.
6. A process for the production of a glycosaminoglycan composition, said process comprising subjecting a homogenate of glycosaminoglycan-containing mammalian intestines to chromatography using a chromatographic matrix, wherein said homogenate is repeatedly applied to said matrix.
7. The process as claimed in claim 5 or claim 6 wherein said mammalian intestines comprise porcine or bovine intestines.
8. The process as claimed in any one of claims 2 to 4 , claim 6 or claim 7 wherein said matrix is in the form of a membrane adsorber.
9. The process claimed in any one of the preceding claims wherein said composition comprises an anticoagulant glycosaminoglycan.
10. The process claimed in any one of the preceding claims wherein said composition comprises heparin.
11. The process claimed in any one of the preceding claims wherein said chromatographic matrix is an anionic exchange membrane.
12. The process as claimed in any one of the preceding claims further comprising depolymerisation and/or fractionation.
13. A glycosaminoglycan composition obtained by the process of any one of the preceding claims.
14. Glycosaminoglycans, particularly anticoagulant glycosaminoglycan or glucosaminoglycans, especially preferably heparins, extracted from krill.
15. The use of the product of claim 13 or claim 14 in medicine.
16. The product of claim 13 or claim 14 for use in medicine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0812919.9A GB0812919D0 (en) | 2008-07-15 | 2008-07-15 | Process |
NO0812919.9 | 2008-07-15 | ||
PCT/GB2009/001784 WO2010007387A1 (en) | 2008-07-15 | 2009-07-15 | Process for producing glycosaminoglycans |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110288283A1 true US20110288283A1 (en) | 2011-11-24 |
Family
ID=39722304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/002,765 Abandoned US20110288283A1 (en) | 2008-07-15 | 2009-07-15 | Process for producing glycosaminoglycans |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110288283A1 (en) |
EP (1) | EP2310421A1 (en) |
JP (1) | JP2011528058A (en) |
CN (1) | CN102124032A (en) |
AU (1) | AU2009272491A1 (en) |
BR (1) | BRPI0915926A2 (en) |
CA (1) | CA2730607A1 (en) |
CL (1) | CL2011000085A1 (en) |
GB (1) | GB0812919D0 (en) |
WO (1) | WO2010007387A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108179162A (en) * | 2018-01-16 | 2018-06-19 | 浙江海洋大学 | A kind of preparation method of low molecular weight heparin |
US20220362283A1 (en) * | 2021-05-12 | 2022-11-17 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6149818A (en) * | 1997-04-01 | 2000-11-21 | Shimadzu Corporation | Method for separating components in liquid specimen and apparatus used in said method |
US6294090B1 (en) * | 1997-03-18 | 2001-09-25 | Sartorius Ag | Adsorptive substance separation device |
US20020111331A1 (en) * | 2000-11-21 | 2002-08-15 | Mckeehan Wallace L. | FGF-affinity chromatography |
US20030127393A1 (en) * | 2001-06-22 | 2003-07-10 | Frederick Tepper | Nanosize electropositive fibrous adsorbent |
US20040026322A1 (en) * | 2002-08-09 | 2004-02-12 | Sartorius Ag | Process and apparatus for adsorptive separation of substances |
US20060065583A1 (en) * | 2002-12-20 | 2006-03-30 | David Buckley | Separation medium and method for its preparation |
US20060246544A1 (en) * | 2005-03-30 | 2006-11-02 | Neose Technologies,Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3244214A1 (en) * | 1982-11-30 | 1984-05-30 | B. Braun Melsungen Ag, 3508 Melsungen | METHOD FOR PURIFYING AND FRACTIONATION OF HEPARIN |
EP0337327A1 (en) * | 1988-04-09 | 1989-10-18 | Bioiberica, S.A. | Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin |
DE19538625C2 (en) * | 1995-10-17 | 1999-08-12 | Sartorius Gmbh | Process for the separation of albumin from serum by membrane ion exchange chromatography |
NZ510539A (en) * | 1998-09-15 | 2003-06-30 | Nizo Food Res | A chromatographic process for producing peptides from biological fluids such as milk, whey, blood, egg white and cell culture extracts |
WO2002076475A2 (en) * | 2001-03-23 | 2002-10-03 | Bioparken As | Glycosaminoglycan anticoagulants derived from fish |
GB0509433D0 (en) * | 2005-05-09 | 2005-06-15 | Uni For Milj Og Biovitenskap | Method |
-
2008
- 2008-07-15 GB GBGB0812919.9A patent/GB0812919D0/en not_active Ceased
-
2009
- 2009-07-15 JP JP2011517996A patent/JP2011528058A/en active Pending
- 2009-07-15 CN CN2009801283700A patent/CN102124032A/en active Pending
- 2009-07-15 WO PCT/GB2009/001784 patent/WO2010007387A1/en active Application Filing
- 2009-07-15 US US13/002,765 patent/US20110288283A1/en not_active Abandoned
- 2009-07-15 CA CA2730607A patent/CA2730607A1/en not_active Abandoned
- 2009-07-15 BR BRPI0915926A patent/BRPI0915926A2/en not_active IP Right Cessation
- 2009-07-15 EP EP09784737A patent/EP2310421A1/en not_active Withdrawn
- 2009-07-15 AU AU2009272491A patent/AU2009272491A1/en not_active Abandoned
-
2011
- 2011-01-14 CL CL2011000085A patent/CL2011000085A1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294090B1 (en) * | 1997-03-18 | 2001-09-25 | Sartorius Ag | Adsorptive substance separation device |
US6149818A (en) * | 1997-04-01 | 2000-11-21 | Shimadzu Corporation | Method for separating components in liquid specimen and apparatus used in said method |
US20020111331A1 (en) * | 2000-11-21 | 2002-08-15 | Mckeehan Wallace L. | FGF-affinity chromatography |
US6812221B2 (en) * | 2000-11-21 | 2004-11-02 | The Texas A&M University System | FGF-affinity chromatography |
US20030127393A1 (en) * | 2001-06-22 | 2003-07-10 | Frederick Tepper | Nanosize electropositive fibrous adsorbent |
US20040026322A1 (en) * | 2002-08-09 | 2004-02-12 | Sartorius Ag | Process and apparatus for adsorptive separation of substances |
US20060065583A1 (en) * | 2002-12-20 | 2006-03-30 | David Buckley | Separation medium and method for its preparation |
US20060246544A1 (en) * | 2005-03-30 | 2006-11-02 | Neose Technologies,Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108179162A (en) * | 2018-01-16 | 2018-06-19 | 浙江海洋大学 | A kind of preparation method of low molecular weight heparin |
US20220362283A1 (en) * | 2021-05-12 | 2022-11-17 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
US11712447B2 (en) * | 2021-05-12 | 2023-08-01 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
Also Published As
Publication number | Publication date |
---|---|
GB0812919D0 (en) | 2008-08-20 |
CN102124032A (en) | 2011-07-13 |
EP2310421A1 (en) | 2011-04-20 |
CA2730607A1 (en) | 2010-01-21 |
AU2009272491A1 (en) | 2010-01-21 |
BRPI0915926A2 (en) | 2015-10-27 |
WO2010007387A1 (en) | 2010-01-21 |
JP2011528058A (en) | 2011-11-10 |
CL2011000085A1 (en) | 2011-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3731150B2 (en) | Purification method of cartilage-type proteoglycan | |
US20090105194A1 (en) | Process for the production of a low molecular weight heparin | |
Vongchan et al. | Anticoagulant activity of a sulfated chitosan | |
JP6755980B2 (en) | High-purity heparin and its manufacturing method | |
WO2017032276A1 (en) | Bovine intestinal mucosa enoxaparin sodium, preparation method therefor, and application thereof | |
Warda et al. | Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin | |
Saravanan et al. | Isolation and characterization of low molecular weight glycosaminoglycans from marine mollusc Amussium pleuronectus (linne) using chromatography | |
Khan et al. | Extraction and biochemical characterization of sulphated glycosaminoglycans from chicken keel cartilage. | |
JP6205350B2 (en) | Chondroitin sulfate sulphated biotechnologically at the 4th or 6th position of the same polysaccharide chain, and a preparation method thereof | |
US20110288283A1 (en) | Process for producing glycosaminoglycans | |
Manjusha et al. | Isolation and characterization of glycosaminoglycans and a study of its bioactive potential in two commercially important species of cephalopods, Loligo duvauceli and Sepia pharaonis | |
JP6444399B2 (en) | Sulfated polysaccharides for use in the treatment of cancer | |
KR20140044826A (en) | Shark-like chondroitin sulphate and process for the preparation thereof | |
JP2003268004A (en) | Chondroitin sulfate derived from cartilage of rajiformes and method for producing the same | |
CN104725532B (en) | A kind of method of chondroitin sulfate and dermatan sulfate content in accurate quantification control heparin/heparan | |
US20040171579A1 (en) | Anticoagulant | |
JP2006089632A (en) | Method for preparing heparin-like substance by using marine organism | |
AU2021101092A4 (en) | Antithrombotic heparinoid extracted from short necked clam, preparation method and use thereof | |
JPS6310601A (en) | Chondroitin sulfate derivative | |
RU2270023C2 (en) | Method for extraction and purification of cartilage-type proteoglycan (variants) | |
Jeske et al. | Isolation and characterization of heparin from tuna skins | |
KR102180261B1 (en) | Method for extraction of heparin derived from by-product of pork | |
CN112076211A (en) | Glycosaminoglycan composition and preparation method and application thereof | |
JP2007224286A (en) | Process for acquiring polysaccharide from living body tissue | |
CN114853920A (en) | Giant salamander cartilage chondroitin sulfate and extraction method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HEPMARIN AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FLENGSRUD, RAGNAR;REEL/FRAME:026070/0859 Effective date: 20110303 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |